Search Result

Results for "

human platelet-rich plasma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) CXCR (1) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (1) HMG-CoA Reductase (HMGCR) (1) Integrin (1) Keap1-Nrf2 (1) P2Y Receptor (2) PARP (1) PCSK9 (1) Phosphodiesterase (PDE) (1) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (5) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (ROS) (1) Thrombin (1) Tyrosinase (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (12) Endocrinology (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (1)

By Targets:

Apoptosis (1)

Autophagy (1)

Bacterial (1)

Biochemical Assay Reagents (1)

CXCR (1)

Drug Derivative (1)

Drug Metabolite (2)

Endogenous Metabolite (1)

HMG-CoA Reductase (HMGCR) (1)

Integrin (1)

Keap1-Nrf2 (1)

P2Y Receptor (2)

PARP (1)

PCSK9 (1)

Phosphodiesterase (PDE) (1)

Platelet-activating Factor Receptor (PAFR) (1)

Prostaglandin Receptor (5)

Protease Activated Receptor (PAR) (1)

Reactive Oxygen Species (ROS) (1)

Thrombin (1)

Tyrosinase (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (12)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (1)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-N1775

3',4'-Dihydroxyacetophenone 3,4-DHAP	Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC₅₀ of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .

HY-128039

17-Phenyl-ω-trinor-PGE2	Prostaglandin Receptor	Others
17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .

HY-123669

R-138727	P2Y Receptor Drug Metabolite	Cardiovascular Disease
R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC₅₀ of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.

HY-135447

BM-531	Prostaglandin Receptor	Others
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

HY-Y1094

[Rh(cod)Cl]2 Chloro(1,5-cyclooctadiene)rhodium(I) dimer	Biochemical Assay Reagents	Cardiovascular Disease
[Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) is a rhodium (I) organometallic dimer complex. [Rh(cod)Cl]2 can inhibit platelet-activating factor-mediated platelet aggregation with IC₅₀ values of 5.2 and 43.3 μM in washed rabbit platelets and human platelet-rich plasmas. [Rh(cod)Cl]2 also can inhibit thrombin-, ADP (HY-W010918)- and collagen-induced aggregation with IC₅₀ values of 16.7, 162 and 69.8 μM. [Rh(cod)Cl]2 can be used for the research of cardiovascular disease, such as thrombosis .

HY-137591

13,14-Dihydro-15-keto-PGE1	Drug Metabolite	Endocrinology
13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC₅₀ 14.8 μg/mL .

HY-19126

CL-184005	Platelet-activating Factor Receptor (PAFR)	Infection Cardiovascular Disease
CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC₅₀ of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .

HY-108561

L-670596	Prostaglandin Receptor	Others
L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069 .

HY-137288

17-Phenyl-18,19,20-trinor-PGD2 17-Phenyl-PGD2	Prostaglandin Receptor	Cardiovascular Disease
17-Phenyl-18,19,20-trinor-PGD2 (17-Phenyl-PGD2) is an analogue of prostaglandin D2 (PGD2; HY-101988). 17-Phenyl-18,19,20-trinor-PGD2 is a potent inhibitor of platelet aggregation caused by aenosine diphosphate (ADP), with the IC₅₀ of 8.4 μM (PGD2 IC₅₀ = 18.6 nM). 17-Phenyl-18,19,20-trinor-PGD2 is a weak agonist of cyclic AMP accumulation .

HY-10312

UR-12947	Integrin	Cardiovascular Disease
UR-12947 is a platelet glycoprotein (GP) IIb-IIIa antagonist. UR-12947 exhibits potent inhibitory activity against platelet aggregation in human platelet-rich plasma, with an IC₅₀ value of 3.5 nM. UR-12947 can be used in the research of arterial thrombotic diseases .

HY-149310A

Dim16 hydrochloride	PCSK9 HMG-CoA Reductase (HMGCR)	Metabolic Disease
Dim16 hydrochloride is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC₅₀ of 0.8 nM against human PCSK9 and an IC₅₀ of 146.8 μM against HMG-CoAR. Dim16 hydrochloride disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 hydrochloride can be used in research related to hypercholesterolemia .

HY-N17826

YM-254891	Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite	Cardiovascular Disease
YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .

HY-183983

PAR4 antagonist 9	Protease Activated Receptor (PAR)	Cardiovascular Disease
PAR4 antagonist 9 is an orally active protease-activated receptor 4 (PAR4) antagonist with an IC₅₀ of 2 nM against human targets. PAR4 antagonist 9 functionally modulates PAR4 and inhibits platelet aggregation. PAR4 antagonist 9 can be used in studies related to arterial thrombosis .

HY-182533

LN5972	CXCR	Cardiovascular Disease
LN5972 is a selective ACKR3 agonist with an EC₅₀ of 3.40 μM, showing higher selectivity for ACKR3 over CXCR4. LN5972 induces β-arrestin recruitment to ACKR3/CXCR7. LN5972 reduces the surface expression of P-selectin. LN5972 is applicable to studies related to platelet-mediated thrombosis .

HY-186042

TPα/β antagonist-1	Prostaglandin Receptor	Cardiovascular Disease
TPα/β antagonist-1 is a TXA2 receptor α (TPα) and TPβ antagonist with IC₅₀s of 1.52 nM and 0.79 nM, respectively. TPα/β antagonist-1 inhibits U-46619 (HY-108566)-induced intracellular calcium mobilization, and imhibits platelet aggregation. TPα/β antagonist-1 can be used for the research of cardiovascular disease .

HY-106830

Pelrinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC₅₀ of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na ⁺/K ⁺-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .

Cat. No.	Product Name	Type

HY-135447

BM-531	Biochemical Assay Reagents
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

BM-531

Biochemical Assay Reagents

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Target	Research Area

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1775

3',4'-Dihydroxyacetophenone 3,4-DHAP	Structural Classification Classification of Application Fields Pinaceae Phenols Polyphenols Picea schrenkiana Fisch. et Mey. Plants Disease Research Fields Source Classification Cancer	Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis
3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC₅₀ of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .

HY-N17826

YM-254891	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite
YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

human platelet-rich plasma

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products